"This latest trial suggests that [nivolumab plus AVD] may become the treatment of choice for all stages of Hodgkin's lymphoma." SWOG S1826 is a phase III, multicenter, randomized trial involving ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback